These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [The use of BCG vaccine in the treatment of surface tumors of the bladder]. Kumanov Kh; Ormanov I; Engibarov A Urol Nefrol (Mosk); 1989; (5):41-4. PubMed ID: 2595863 [TBL] [Abstract][Full Text] [Related]
26. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2]. Wen R; Zhou G; Xie S; Lian B; Sun X; Chen J Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):247-8. PubMed ID: 11825381 [TBL] [Abstract][Full Text] [Related]
30. [Effect of prophylactic intravesical instillation of BCG for superficial bladder cancer]. Segawa N; Inamoto T; Nomi H; Ibuki N; Azuma H; Katsuoka Y Hinyokika Kiyo; 2009 Apr; 55(4):175-80. PubMed ID: 19462820 [TBL] [Abstract][Full Text] [Related]
31. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer. Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665 [No Abstract] [Full Text] [Related]
32. [Treatment of PT1 tumors of the bladder using transurethral resection and intravesical immunotherapy]. Bertault D; Benoit G; Vieillefond A; Ribaud P; Bensadoun H; Jardin A Ann Urol (Paris); 1990; 24(2):97-101; discussion 102. PubMed ID: 2350169 [TBL] [Abstract][Full Text] [Related]
33. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer. Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662 [No Abstract] [Full Text] [Related]
35. [BCG therapy. Its role in the treatment of tumors of the bladder]. Patard JJ; Chopin DK; Abbou CC Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911 [No Abstract] [Full Text] [Related]
36. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729 [TBL] [Abstract][Full Text] [Related]
37. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale, design, and interim analysis of the trial of the South-East Cooperative Urological Group, The Netherlands. Witjes WP; van der Meijden PM; Roos EP; Witjes JA; Steerenberg PA; Doesburg W; Debruyne FM Prog Clin Biol Res; 1992; 378():59-67. PubMed ID: 1301587 [No Abstract] [Full Text] [Related]
38. [The treatment of superficial bladder carcinoma with intravesical bacillus Calmette-Guerin]. Jitsukawa S; Tachibana M; Deguchi N; Baba S; Hata M; Tazaki H; Nakazono M Nihon Hinyokika Gakkai Zasshi; 1987 May; 78(5):822-7. PubMed ID: 3694980 [No Abstract] [Full Text] [Related]
39. BCG in the management of superficial bladder cancer. Guinan P; Richardson C; Hanna M; Rubenstein M Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002 [TBL] [Abstract][Full Text] [Related]
40. [Long-term results and complications of intravesical instillation of bacillus Calmette-Guerin for prophylaxis of bladder cancer recurrence]. Irie A; Lee KE; Kadowaki K; Sawamura M Hinyokika Kiyo; 1994 Oct; 40(10):873-7. PubMed ID: 7992700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]